The Aleva Neuro Team


A group of executives with track-proven record of success in the medical device industry and expertise on Commercialisation, Operations, Clinical Investigation and Research & Development.

Alexandre Grassin CFO Aleva

Alexandre Grassin

Alexandre joined Aleva in June 2021 to support the Company in the transition towards commercialization. Prior to Aleva, Alexandre was CFO / VP of Finance and Administration at Genkyotex, a Swiss biotech company listed on Euronext Paris and Brussels. Alexandre played a key role in the Reverse Take Over (RTO) process through which Genkyotex became public in 2017 and in the strategic combination with Calliditas Therapeutics in 2020/2021.

Alexandre has more than 20 years of industry experience mainly in the Pharma/Biotech/Medtech sector in Switzerland with Genkyotex, Alexion and Novartis. He started his career in 2000 as a financial auditor working for KPMG in Paris.

André Mercanzini, PhD

His doctoral thesis on the in vivo application of neurological implants formed Alevaʼs core technology. He gained product development experience at MIT Artificial Intelligence Laboratory, Zyvex Corporation (TX, USA) and Bosch Research (Silicon Valley, USA).

He holds over 10 international patent families on neuromodulation and micro-assembly of medical devices. André obtained his BS in Engineering Physics from the University of Toronto, MS in Management Science from Stanford University, and PhD in Biomedical Engineering from the EPFL, Switzerland.

André Mercanzini Founder Aleva
Alain Jordan COO Aleva

Alain Jordan, MSc

Alain has more than 20 years of experience in development and manufacturing of active implantable devices. As first employee of Endoart SA, he was playing a key role in all aspects of project and technology management. He has a thorough knowledge of EU and US requirements relative to the development and production of active implantable devices.

After the acquisition of Endoart SA by Allergan Inc., he was leading a multidisciplinary team of 28 people involved in the development and manufacturing of active implantable devices. Alain obtained his MS in Microengineering from EPFL, and his Postgraduate Degree in Biomedical Engineering from EPFL, Lausanne University and Geneva University, Switzerland.

Alain Dransart, MSc

Alain has extensive experience in medical devices, first with Haemonetics Corporation (automated blood separation), then with Medtronic Europe (pacemakers and heart valves), and most recently as a consultant in Product Management, Market Analysis and Clinical Management.

He has led clinical validation of new products, market research, and product launch in Europe. Alain obtained his MS in Electrical Engineering from EPFL and followed the PED management program at IMD, Switzerland.

Alain Dransart Aleva
Karl-Matthias Möhlmann

Karl Matthias Moehlmann, MD

Matthias brings more than twenty years of experience as an executive or advisor for leading medical device companies in the neurological, trauma and orthopedic categories to Aleva.

Prior to joining Aleva in January 2020, Matthias  held leadership and consultancy roles at Nevro, aap Bioimplants, Benvenue Medical, DePuy Spine and Kyphon (acquired by Medtronic), focussed on clinical and product to market implementation in addition to his clinical expertise as an intensive care and emergency physician. 

Diego Polzoni

Diego is an experienced international MedTech leader. Focused on Neuroscience, he has 17 years’ experience in both startup and multinational corporations developing multinational and multicultural management skills.

He took part of Boston Scientific’s Neuromodulation platform launch from the beginning, successfully embracing different European roles: sales agent, marketing and product management, field sales and country business management.

Diego developed an acute expertise in creating market momentum during his leadership of EMEA teams. Developing the business for the ROSA Brain robotic platform in startup mode, and during and following  the transition to Corporate after the acquisition by Zimmer Biomet. Diego managed the business growth and team doubling through the years.

Diego Joined Aleva in December 2021 to develop new market opportunities on the commercial side and managing successful partnerships to respond to customer’s needs to “improve the lives of Patients by providing personalized support throughout the full patient journey while continually developing our DBS technology, products and services”, as per our MISSION

Diego Polzoni Aleva

With a large team of specialised people with expertise in DBS technology applied to Neurological and Psychiatric diseases, Aleva is well suited to be a significant player in the European DBS market. 

Contact us to receive a visit from the sales specialists closest to you.